Stock Price of Teva Pharmaceutical Industries Limited (TEVA) Decreases -6.53%

Teva Pharmaceutical Industries Limited s in-depth stock price analysis indicates that the stock price has dropped -16.52% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -37.56% . Looking at the past 52 week period, the stock price is down -42.26% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Teva Pharmaceutical Industries Limited has a negative value of -32.26 compared to overall market performance. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has tumbled 6.53% during the past week and has dropped 5.24% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.29%. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has underperformed the index by 6.94% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.06 points or 0.19% at $32.19 with 13,823,830 shares getting traded. Post opening the session at $32, the shares hit an intraday low of $31.92 and an intraday high of $32.5 and the price was in this range throughout the day. The company has a market cap of $32,673 million and the number of outstanding shares has been calculated to be 1,015,000,000 shares. The 52-week high of Teva Pharmaceutical Industries Limited (NYSE:TEVA) is $59.345 and the 52-week low is $31.9.

Teva Pharmaceutical Industries Ltd (ADR) Last issued its quarterly earnings results on Nov 15, 2016. The company reported $1.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $1.28. The company had revenue of $5563.00 million for the quarter, compared to analysts expectations of $5713.21 million. The companys revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.35 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by Mizuho on Feb 10, 2017 to Neutral, Lowers Price Target to $ 27 from a previous price target of $40 .Teva Pharmaceutical Industries Ltd (ADR) was Upgraded by BofA/Merrill to Buy on Jan 31, 2017. Teva Pharmaceutical Industries Ltd (ADR) was Reiterated by Barclays on Jan 31, 2017 to Equal Weight, Lowers Price Target to $ 38 from a previous price target of $46 .Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by JP Morgan to Neutral on Jan 20, 2017. Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by Wells Fargo to Market Perform on Jan 9, 2017.

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.

Teva

Share this post

Leave a Reply